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A novel perspective of the function of carotenoids and carotenoid-derived products  including, but not
restricted to, the retinoids  is emerging in recent years which connects these compounds to the control
of adipocyte biology and body fat accumulation, with implications for themanagement of obesity, diabetes
and cardiovascular disease. Cell and animal studies indicate that carotenoids and carotenoids derivatives
can reduce adiposity and impact key aspects of adipose tissue biology including adipocyte differentiation,
hypertrophy, capacity for fatty acid oxidation and thermogenesis (including browning of white adipose tis-
sue) and secretory function. Epidemiological studies in humans associate higher dietary intakes and serum
levels of carotenoids with decreased adiposity. Speciﬁcally designed human intervention studies, though
still sparse, indicate a beneﬁcial effect of carotenoid supplementation in the accrual of abdominal adiposity.
The objective of this review is to summarize recent ﬁndings in this area, place them in physiological con-
texts, and provide likely regulatory schemes whenever possible. The focus will be on the effects of carote-
noids as nutritional regulators of adipose tissue biology and both animal and human studies, which support
a role of carotenoids and retinoids in the prevention of abdominal adiposity.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Carotenoids are lipophilic C-40-based isoprenoid pigments usu-
ally red, orange or yellow in color which are produced by plants
and certain photosynthetic microorganisms. Primary dietary
sources are fruits and vegetables, though they can also be obtained
from bread, eggs, milk, beverages, fats, and oils. Of 600 carote-
noids in nature, 50 are present in the human diet, but only six
are ubiquitous in human serum, namely b-carotene (BC),1
a-carotene, b-cryptoxanthin, lycopene, lutein, and zeaxanthin [1].
The main known function of carotenoids in humans is to serve
as precursors of vitamin A related retinoids such as retinol, retinaland retinoic acid that play important roles in the visual cycle and in
gene regulation linked to many developmental and physiologic
processes [2]. Intact carotenoid molecules and carotenoid cleavage
products other than the retinoids may have additional biological
activities whose relevance for human health is still uncertain,
including acting as antioxidants and blue light ﬁlters for photopro-
tection [3,4]. BC is the main provitamin A carotenoid in the human
diet. Key to retinoid production from BC in mammals is the activity
of b-carotene-15,150-oxygenase (BCO1), a cytosolic enzyme that
cleaves BC centrally into two molecules of retinal (also named reti-
naldehyde, Rald), which can be oxidized irreversibly to retinoic
acid or reduced reversibly to retinol [5] (Fig. 1). BCO1 is speciﬁcalma de
adipose
cluster of
xysteroid
, nuclear
or RBP4),
tor; SAT,
ue; WAT,
STRA6 
RBPR2
RE 
ADH 
RDH 
ALDH1 
genomic eﬀects
nucleus
oxidized 
products
CYP 
BCO1
BC 
± 
LRAT        REH
lipoproteins
RA 
CRABP 
FABP5  
Rald 
CRBP 
ROL
CRBP 
ROL
RBP 
RE 
BC 
lipoprotein 
receptors
LPL
excreon
lipid 
droplet
RA 
albumin
BCO2
β-apo- 
carotenoids 
BC 
mitochondria
? 
NRs 
BC 
Fig. 1. Overview of cellular retinoid and b-carotene metabolism. Circulating retinol (ROL) bound to retinol binding protein (RBP) is internalized in peripheral cells through the
action of speciﬁc surface receptors (STRA6, RBPR2) or by diffusion across the plasma membrane. Efﬁcient ROL uptake depends on its binding to the cellular retinol binding
protein (CRBP) and the activity of lecithin:retinol acyltransferase (LRAT) in esterifying ROL to fatty acids to form retinyl esters (RE) which incorporate into lipid droplets. RE
associated with circulating lipoproteins can be hydrolyzed to ROL by lipoprotein lipase (LPL) and taken up by the cells. Alternatively, circulating lipoproteins containing RE
and carotenoids such as b-carotene (BC) can be internalized in cells whole by endocytosis, mediated by lipoprotein receptors. Within the cell, RE is hydrolyzed by RE
hydrolases (REH) to ROL, which can be reversibly oxidized to retinaldehyde (Rald) by short-chain dehydrogenase/reductases with retinol dehydrogenase (RDH) activity or
medium-chain alcohol dehydrogenases (ADH) able to use retinol as a substrate. Rald can also be produced from BC, through symmetric cleavage catalyzed by b-carotene-
15,150-oxygenase (BCO1). BC (and other carotenoids, not shown) can be asymmetrically cleaved through the action of mitochondrial b-carotene-90 ,100-oxygenase (BCO2).
Some BCO2 products can be converted into Rald, with the participation of BCO1. Rald is irreversibly oxidized to retinoic acid (RA) by the action of aldehyde dehydrogenases
(ALDH1). RA can be taken up from the circulation where it is found bound to albumin. RA is transferred from the cytoplasm to the nucleus in association with speciﬁc
intracellular lipid binding proteins (CRABP and FABP5). RA, Rald and other BC derivatives exert genomic effects by modulating the activity of distinct nuclear receptors (NR)
and other transcription factors (not shown) in direct and indirect manners. These compounds exert as well non-genomic effects in cells (not shown). RA is catabolized by the
cytochrome enzymes (CYP) to more oxidized products that are eliminated from the cell.
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ed b-ionone ring, such as BC, a-carotene and b-cryptoxanthin.
Mammals express a second BC cleavage enzyme, b-carote
ne-90,100-oxygenase (BCO2), which localizes to mitochondria,
cleaves BC asymmetrically to generate diverse b-apocarotenals
and b-apocarotenones, and has a broad substrate speciﬁcity as it
metabolizes, for instance, the acyclic carotene lycopene and oxy-
genated carotenoids (i.e. xanthophylls, such as lutein and zeaxan-
thin) besides cyclic carotenes [5]. BCO1 and BCO2 are broadly
expressed in mammalian tissues; such widespread expression,
together with the wide distribution of carotenoids in animal tis-
sues, has suggested that local, tissue-speciﬁc conversion of carote-
noids may contribute to the in situ generation of retinoids and
other apocarotenoids that impact tissue metabolism [5].
In recent years, a novel perspective of the function of carote-
noids and carotenoid-derived products  including, but not
restricted to, the retinoids  is emerging that connects these com-
pounds to the control of body fat accumulation, with implications
for the management of obesity and obesity-related metabolic dis-
turbances [6–10]. Although effects on body fat content can relate
to action in different tissues – among them the liver, which consti-
tutes the main reservoir for carotenoids and vitamin A and whose
lipid metabolism is indeed affected by retinoids [10] – cell and ani-
mal studies indicate that adipose tissue is an important target of
carotenoid action. This evidence is the focus of this review. Webegin by brieﬂy presenting mechanisms of action that underlie
the biological activity of carotenoids and carotenoid cleavage prod-
ucts, and the various lines of evidence that implicate these com-
pounds as players in adipose tissue biology. While BC as the
main provitamin A carotenoid is in the center of this review, other
carotenoids active in the modulation of adipocyte biology and body
adiposity are also given consideration. We review the impact of
these compounds on body adiposity and their interaction with
key aspects of adipose tissue biology as revealed by cell and animal
studies, namely: adipocyte differentiation, adipocyte capacity for
fat storage and oxidative metabolism/thermogenesis, and the
secretory and inﬂammatory proﬁle of adipose tissue. Human epi-
demiological and intervention studies addressing the relationship
between carotenoids and vitamin A status and obesity and related
metabolic diseases are speciﬁcally addressed.Mechanisms of action of carotenoids and carotenoid
derivatives
Collectively, carotenoids and carotenoid conversion products
have been shown to impact gene expression and cell (including
adipocyte) function through multiple mechanisms, notably by:
(a) interacting with several transcription factors of the nuclear
receptor superfamily, such as the canonical retinoic acid receptors
Fig. 2. Carotenoids and carotenoid derivatives as modulators of nuclear hormone receptors. The scheme shows BC derivatives (retinoids and other b-apocarotenoids, in bold)
and other carotenoids or carotenoid derivatives that appear to be able to directly interact with the nuclear receptors retinoic acid receptor (RAR), retinoid X receptor (RXR)
and peroxisome proliferator activated receptors (PPARs) to function as agonist or antagonist ligands (see text for details and references).
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erator activated receptors (PPARs), among others; (b) interfering
with the activity of other transcription factors, such as activator
protein-1, nuclear factor jB (NF-jB) or CCAAT-enhancer binding
proteins (C/EBPs); (c) modulating signaling pathways such as the
NF-jB and the nuclear factor erythroid 2-related factor 2 (Nrf2)
pathways, which are associated with inﬂammatory and oxidative
stress responses, respectively; and (d) through extragenomic
actions including scavenging of reactive species, retinoylation
(acylation by retinoic acid) of proteins and activation of protein
kinase cascades [10–13]. All of these mechanisms contribute to
their action in adipocytes, as we shall further see in upcoming
sections.
Gene expression control by retinoic acid has been most studied
[14]. Retinoic acid isomers are agonist ligands of the RARs (RARa,
RARbandRARc) and theRXRs (RXRa, RXRbandRXRc): all-trans reti-
noic acid (atRA) binds the RARs, whereas 9-cis retinoic acid binds
both the RARs and the RXRs. Heterodimers of RAR with RXR control
the expression of typical retinoid-target genes by binding to deﬁned
retinoic acid response elements in the gene promoter andmodulat-
ing transcription in a manner that depends on atRA binding to the
RAR moiety and subsequent recruitment of transcriptional
co-regulator complexes [14]. RXRs are obligate dimerization part-
ners for many other nuclear receptors, including the PPARs. Some,
RXR heterodimers respond to ligands of either partner and are syn-
ergistically activated when both ligands are bound, providing a
mechanism for widespread effects of retinoids on gene expression
[15]. Moreover, besides activating the canonical RARs, evidence
has been provided that atRA (but not 9-cis retinoic acid) can behave
as an activating agonist ligand of PPARb/d (but not the other PPAR
isoforms, namely PPARa and PPARc) [16]. Besides retinoic acid,
other retinoids (such as Rald) as well as apocarotenoids different
from retinoids (such as b-apo-140-carotenal, b-apo-13-carotenone
and apo-100-lycopenoic acid) interact with nuclear receptor
transcription factors to either antagonize or promote their action
on target genes in cells [17–22] (Fig. 2). Even intact carotenoidmole-
cules appear to be able to interact physicallywith nuclear receptors:
studies have suggested that, in differentiating adipocytes, astaxan-
thin can behave as a PPARc antagonist ligand [23] and
b-cryptoxanthin, as a RAR agonist ligand [24] (Fig. 2).Carotenoids and carotenoid derivatives as players in adipose
tissue biology: lines of evidence
Adipose tissue is an important site of carotenoid storage [25].
Within the adipocyte, carotenoids are mainly stored with triacyl-
glycerol in the lipid droplet, and are also found in cell membranes
[26]. In humans, carotenoid levels in abdominal depots show a
strong association with both intake and plasma concentrations
[27,28]. Total carotenoid concentration is higher in abdominal adi-
pose tissue than adipose tissue from buttock and thigh in humans
[27]. However, the mechanisms involved in fat depot-speciﬁc
uptake of carotenoids are unknown, and a recent report concluded
that whole-body adipocyte stores of BC are more or less constant
(130 ± 70 (mean ± SD) lmole per person) regardless of different
body mass index (BMI) and varied intakes of BC, which raises ques-
tions regarding what function it serves and how this constancy is
achieved [29]. Adipose tissue is also an important site for retinol
storage. An early study estimated that 15–20% of the total body
retinol in rats is stored in adipose tissues, in particular in the adi-
pocytes (rather than the stromal vascular cells) and mostly in the
form of non-esteriﬁed retinol (as opposed to preferential storage
as retinyl ester in the liver) [30]. Other retinoids including atRA
and Rald have been detected in adipose tissue [18,31].
Importantly, adipose tissue expresses all intracellular binding pro-
teins and enzymes involved in retinol and retinoic acid production
and metabolism, including BCO1 and BCO2 [7,8], and it also pro-
duces and secretes RBP [30], enabling exportation of retinol to
the circulation.
Provitamin A carotenoids and retinol in adipocytes may serve to
regulate systemic vitamin A homeostasis. In fact, adipose reti-
nol/retinyl esters stores are readily mobilized under conditions of
dietary vitamin A deﬁciency, as evidenced by decreased levels
[9]. Additionally, carotenoids, vitamin A and their derivatives
may serve speciﬁc functions within the mature adipocytes, includ-
ing the control of metabolism (relative capacities for fat storage
and oxidation), oxidative stress and production of inﬂammatory
mediators (see also the upcoming sections). These aspects may
be of special relevance in regard to obesity, as obesity entails the
development of hypertrophic adipocytes in which oxidative stress
is exacerbated [32] and inﬂammation of adipose tissue [33].
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vitamin A and their metabolites in fat depots in connection with
adipose tissue development and function are technically
challenging and lacking, yet the importance of carotenoids and
retinoids for adipose tissue biology is supported by various lines
of evidence:
(i) Studies suggest crosstalk of intracellular retinoid metabolism
and lipid droplet dynamics. Hormone sensitive lipase (HSL) hydro-
lyzes retinyl esters besides triacylglycerol stored in lipid droplets
[34]. Furthermore, the proteome of the lipid droplet includes
enzymes of retinoid metabolism, such as the retinol dehydroge-
nase Rdh10, which catalyzes retinol to Rald conversion, and the
retinal reductase Dhrs3, which preferentially catalyzes the oppo-
site reaction ([35] and references therein). Interestingly, asso-
ciation of enzymes of retinoid metabolism with the lipid droplet
coat seems to be dependent on active acyl ester biosynthesis
[35,36]. For instance, in COS7 cells, Rdh10 localizes to mitochon-
dria or mitochondrial-associated membrane and relocates to the
surface of the lipid droplets upon active acyl ester biosynthesis
[35]. It is conceivable, therefore, that synthesis of Rald and retinoic
acid is increased under conditions of net lipid droplet enlargement.
It would be interesting to know if relocation events take place as
well in adipocytes, and whether BC cleavage enzymes also relocate
to lipid droplets (which contain carotenoids) in a regulated
manner.
(ii) Animal and human studies reveal a differential expression of
genes for carotenoid/retinoid metabolizing enzymes in visceral
(VAT) and subcutaneous (SAT) adipose tissue [17,37–41]. This fur-
ther suggests a role of endogenous retinoid metabolism in the con-
trol of adipose tissue function and dynamics, since VAT and SAT
display important differences regarding genetic origin, metabo-
lism, endocrinology, capacity for adipogenesis and the health risk
they entail; VAT is generally considered to be more strongly corre-
lated with elevated risk for metabolic dysfunction and cardiovas-
cular disease, while SAT may even be protective [42]. Recently,
VAT obtained from the omental apron of patients with extreme
obesity (mean BMI: 56.8 kg/m2) undergoing open Roux-en-Y gas-
tric bypass showed BCO2 as one of 66 uniquely expressed genes
in this depot as compared to subcutaneous or epigastric fat by
microarray analysis [39]. Because, as already stated (Fig. 2), BCO2
speciﬁc products can antagonize the activation of RARs [19], RXR
[20,21] and PPARs [20] in cells including adipocytes, increased
BCO2 activity on stored target carotenoids might result in
decreased signaling through RAR:RXR and PPAR:RXR in VAT as
compared to SAT. As we shall see next, this could contribute to a
relatively lower capacity for oxidative metabolism and adipoge-
nesis and changes in adipokine secretion in VAT, all of which could
be of pathophysiological signiﬁcance.
Increased BCO2 signaling in VAT vs SAT may accompany
increased retinoid metabolism in the visceral fat depots.
Comparable levels of retinol were reported in VAT and SAT depots
in rodents [30,37], but murine VAT has higher expression levels of
various retinoid homeostatic genes compared to SAT [37].
Accordingly, studies in humans (including two non-targeted pro-
teomic studies) showed increased mRNA and protein levels of a
main enzyme in the conversion of Rald to atRA  Aldh1a1, also
known as Raldh1  in VAT as compared to SAT [17,40,41]. One
study reported a direct association between Aldh1a1 expression
in human VAT and BMI (r2 = 0.39, P < 0.001) [17]. The latter result
might be in keeping with the somewhat reciprocal ﬁnding of
decreased visceral fat and resistance to diet-induced obesity and
associated insulin resistance in knockout mice lacking Aldh1a1
[17,18,38]. These results would suggest a detrimental effect of adi-
pose Aldh1a1 activity in regard to obesity and its sequela. Another
human proteomic study, however, found decreased levels of
cytosolic Aldh1a1 protein in VAT of pre-obese diabetic subjectsas compared with their non-diabetic counterparts [43], suggesting
a beneﬁcial effect of adipose Aldh1a1 activity.
(iii) Genetic ablation of various carotenoid/retinoid-metaboliz
ing enzymes and transport proteins – such as BCO1, Aldh1a1,
Rdh1, retinol saturase and cellular retinol binding proteins I and
III – results in alterations of adipose tissue in mice (reviewed in
[9]). This supports a role of endogenous carotenoid/retinoid meta-
bolism in the control of adipose tissue development and function,
although caution should be made since substrate speciﬁcity of
some of the enzymes ablated (Aldh1a1, Rdh1 and retinol saturase)
is broad, and therefore action on other targets might contribute or
even be responsible for the observed adipose phenotype. The phe-
notype of most of these mutant models has been reviewed else-
where [9]. To be highlighted is that BCO1/ mice are more
susceptible to diet-induced obesity and show increased expression
of PPARc-induced genes in VAT compared with their wild-type
counterparts [44], which already suggested an anti-adiposity
action of BCO1 conversion products.
(iv) Finally, the connection of carotenoids and retinoids with
adipose tissue biology is sustained by treatment/supplementation
studies, most of them in animals, which indicate an impact on
body adiposity together with major effects on the adipose tissue
capacities for fat storage, fat burning and secretory function, even
if for some of these compounds changes in energy and lipid meta-
bolism in other tissues, such as skeletal muscle [45–47] and the liv-
er [48–50] are also involved. This line of evidence is developed in
detail in next sections.Animal studies linking BC and vitamin A to body adiposity
An adiposity-reducing effect of dietary BC supplementation
(35 mg/kg bw/day, 14 weeks), not accompanied by changes in
body weight or energy intake, has been demonstrated in mice
[51]. Importantly, this effect is dependent on BC conversion to reti-
noids via BCO1, as it was not seen in BCO1/ mice, despite these
mutants accumulated large amounts of BC and of the BCO2 product
b-100-apocarotenol (derived from BC) in white fat following sup-
plementation [51]. These results are in keeping with studies in
3T3-L1 white adipocytes showing reduction of accumulated lipids
following BC treatment (2 lM) [52]. In seeming disagreement,
6-months BC supplementation (3.2 mg/kg bw/day) resulted in
increased body weight (by 14%) and subcutaneous (inguinal) fat
mass (by 16%) in ferrets [53,54]. Since the anti-adiposity action
of BC requires its conversion to retinoids [51], the difference may
relate to previous ﬁndings that ferrets are not as efﬁcient as
humans and rodents in converting BC to vitamin A [55]; in fact,
in the same study, treatment with atRA decreased body fat and adi-
pocyte size in ferrets [54].
Further sustaining an anti-adiposity effect of BC-derived reti-
noids, work of different groups including ours has shown that
atRA treatment (from 0.25 to 100 lg/g bw/day, through various
routes of administration and for different duration) reduces adi-
posity and enhances glucose tolerance and insulin sensitivity in
both lean and obese rodents [34,47,48,56–63]. Treatment with
atRA has also been shown to counteract the development of diet-
ary obesity in obesity-prone mice [64]. The anti-adiposity action
of atRA has been traced to increased oxidative metabolism and
energy expenditure in different tissues including white adipose tis-
sue (WAT) and to decreased PPARc expression and activity in WAT
depots, with the involvement of both RAR and PPARb/d activation
(see Section Impact of BC and BC derivatives on the metabolic pro-
ﬁle of adipocytes). The immediate precursor of atRA, Rald, also
appears to have an anti-adiposity effect per se in vivo, since mice
lacking Aldh1a1 had increased Rald levels in WAT and resisted
diet-induced obesity [18], in vivo knockdown of Aldh1a1 in WAT
116 M. Luisa Bonet et al. / Archives of Biochemistry and Biophysics 572 (2015) 112–125(through antisense oligonucleotide) limited diet-induced obesity
[17] and administrating Rald or a Aldh1 inhibitor decreased subcu-
taneous fat mass in obese ob/ob mice [18]. Aldh1a1 is the main
aldehyde dehydrogenase involved in atRA production from Rald
in adipocytes/adipose tissue [37,38]. Similar to atRA treatment,
the anti-adiposity effect of Aldh1a1 knockout/knockdown
involves up-regulation of energy expenditure in WAT [17] (see
Section Impact on adipocyte capacity for oxidative
metabolism/thermogenesis).
Additional dietary studies in animals link vitamin A status to
adiposity. Diets low in carotenoids and vitamin A are used tradi-
tionally to favor the development of adipose tissue and the forma-
tion of intramuscular fat in the cattle [65,66], the so-called bovine
marbling. In good concordance, chronic vitamin A-deﬁcient diet
feeding increases adiposity in rodents [58,67] this correlating with
enhanced PPARc expression in WAT depots [58]. Reciprocally,
chronic dietary vitamin A supplementation (as retinol or retinyl
palmitate, at 40- to 50-fold the control dose) led to decreased
WAT mass in both lean rats [68] and genetically obese WNIN/Ob
rats [69–71]  although in one of the studies at the expense of
increased serum and liver lipids [70]. In the WNIN/Ob rats, vitamin
A supplementation resulted in decreased 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1) activity in liver and visceral
WAT, suggesting that decreased glucocorticoid signaling might
be another mechanism by which vitamin A modulates adiposity
[71]. 11b-HSD1 catalyzes the intracellular regeneration of active
glucocorticoids from inert derivatives, thus amplifying local gluco-
corticoid action, which is known to promote preadipocyte differen-
tiation. However, vitamin A supplementation had only a modest
effect counterbalancing the development of diet-induced obesity
in obesity-prone mice [45], and it did not affect body weight and
adiposity gain in response to a cafeteria diet in rats [72].
Moreover, there are studies pointing to a pro-obesogenic effect of
excess intake of preformed vitamin A (retinol) in critical periods
in early life, through mechanisms that may relate to changes in
WAT development [73,74] (see Section Impact of BC and BC deriva-
tives on adipogenesis next).
Impact of BC and BC derivatives on adipogenesis
Adipose tissue is highly plastic and can adapt to facilitate
greater energy storage through the hypertrophic expansion of
terminally-differentiated mature adipocytes as well as the hyper-
plastic growth and differentiation of precursor cells resident in
the stroma. The latter process (adipogenesis) is triggered by nutri-
tional and hormonal signals that activate a cascade of transcription
factors that includes various C/EBPs and PPARc, which is consid-
ered the master regulator of adipogenesis (reviewed in [75]).
Even in (human) adult adipose tissue, about 10% of adipocytes turn
over every year [76] and adipogenesis can be induced by environ-
mental cues such as consumption of a high fat diet, both in rodents
[77] and humans [78]. Proper adipogenesis is critical for maintain-
ing health, as impairments in the face of a positive energy balance
(i.e. more energy ingested than expended per day) may result in
ectopic fat deposition and lipotoxicity, leading to insulin resis-
tance, diabetes and vascular complications [79]. However, many
obese humans have more than the average number of adipocytes
and weight loss decreases the volume of adipocytes but not adipo-
cyte number [80]. This may facilitate body weight regain. In fact,
studies in rodents have suggested that increased adipocyte number
might per se lead to obesity [81]. In this context, the control of adi-
pogenesis emerges as a potential co-adjuvant therapeutic target in
obesity when coupled to strategies enhancing a negative energy
balance. Agents capable of tipping the adipocyte birth–death bal-
ance in favor of reducing the number of fat cells become of poten-
tial interest [80].BC (50 lM) was shown to inhibit adipose conversion of 3T3-L1
preadipocytes, the prototypical model for studies of adipogenesis
[82]. This is most likely due to BC conversion into atRA, for which
an inhibitory effect on adipogenesis is well known [83,84].
Inhibition of adipogenesis by atRA is explained by several
non-mutually exclusive mechanisms which translate into repres-
sion of PPARc. One is the interference of liganded RAR with the
activity of the early adipogenic transcription factor C/EBPb on its
downstream target genes in the adipogenic program [84], through
the RAR-dependent induction of the C/EBPb inhibitory protein
Smad3 [85]. Additionally, atRA works upstream C/EBPb in preadi-
pocytes by inducing – at the transcriptional level and through an
RAR pathway – speciﬁc proteins that inhibit adipogenesis, namely
Pref-1, Sox9 and KLF2 [64]. Retinoylation of regulatory proteins
leading to decreased PPARc availability for transcription regulation
may also play a role, this one independent of RAR and RXR [86].
Promotion of apoptosis of primary rat preadipocytes and clonal
preadipocytes by atRA has also been reported [87,88]. Inhibition
of adipogenesis is unlikely to contribute to the body fat reduction
elicited by short-term atRA treatment in animals, but it has been
shown to contribute to the protective effect of chronic atRA treat-
ment against the development of high fat diet-induced obesity in
mice [64].
BC metabolites other than atRA have been shown to repress adi-
pogenesis of preadipocyte cell lines, in particular Rald [18,82] and
b-apo-carotenals resulting from asymmetric cleavage of BC, such
as b-apo-80-carotenal [82] and, especially, b-apo-140-carotenal
[20]. Both Rald and b-apo-140-carotenal behave as weak RAR ago-
nists [18,20], yet their inhibitory effect on adipogenesis has been
traced to their ability to suppress PPARc- and RXR-mediated
responses through RAR-independent mechanisms, possibly follow-
ing direct physical binding to these receptors [18,20].
Because the transcriptional landscape changes dynamically
during adipogenesis and RXR activation can affect signaling by
many nuclear receptors, it is not surprising that atRA effects on
adipogenesis are complex and both differentiation stage- and
concentration-dependent events. Adding atRA to preadipocytes in
high doses (0.1–10 lM) at the early stages of adipogenic differen-
tiation has an inhibitory effect [83,84]. In contrast, adding atRA at
lower doses (1 pM to 10 nM range) promotes adipogenic conver-
sion [89]. Moreover, stem cell commitment into the adipocyte lin-
eage requires a time-deﬁned treatment with atRA [90], and
endogenous atRA production appears to be required for efﬁcient
adipogenesis of 3T3-L1 ﬁbroblast cell lines, by favoring PPARc
expression through zinc-ﬁnger protein 423-dependent mechan-
isms [38]. Therefore, it is possible that increased adiposity seen
in animals chronically fed diets low in vitamin A [58,65] relates
to proadipogenic effects of low atRA doses. Studies in HSL deﬁcient
mice support the concept that atRA can be pro- or anti-adipogenic
in vivo depending on the dose [34]. HSL-null mice display
decreased atRA levels in WAT (reﬂecting the lack of the retinyl
ester hydrolase activity of HSL) and have defective adipogenesis
in response to a high fat diet; dietary atRA supplementation partly
restored WAT in these mutants, in which it would have served to
restore atRA levels back to normal or near-normal levels, whereas
it lowered WAT in the wild-type animals [34].
Nutritional clues at critical stages in early life can affect the sus-
ceptibility to metabolic alterations and diseases including obesity
later in life (reviewed in [91]). In this context, the ultimate impact
of vitamin A supplements on body adiposity might be develop-
mental stage-dependent. For instance, in line with an
anti-adipogenic action of retinoids, we recently reported that treat-
ment with a moderate, threefold excess vitamin A (as retinyl ester)
during the suckling period – which is a critical period in the devel-
opment of adipose tissue in the rat – favors the accumulation of
immature adipocytes, smaller and with less expression of PPARc
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proliferative status [74]. These changes apparently boosted the
hyperplasic component of fat expansion upon an obesogenic sti-
mulus, since vitamin A-treated animals gained more adiposity –
but not body weight – than their controls on a high fat diet, par-
ticularly subcutaneous fat, paralleling a higher increase in WAT
DNA content [74]. A previous report already evidenced a synergic
effect of exposure to a fourfold excess vitamin A (retinol) and high
fat diet on WAT mass expansion in young (3-weeks-old) rats,
which paralleled a higher proliferation competence of precursor
cells isolated from the animals’ fat depots [73]. These studies point,
therefore, to a pro-obesogenic effect of excess vitamin A intake
(even if moderate) in early life, likely by inﬂuencing the prolif-
erative status of adipocytes. Interestingly, different from pre-
formed vitamin A intake, a threefold excess vitamin A intake as
BC during the suckling period did not elicit changes in the develop-
ing WAT of rats at weaning, even though BC was readily absorbed
and partially metabolized by the suckling rats, as indicated by BC
accumulation in serum and liver and enhanced atRA-dependent
responses in intestine and liver [92]. This latter work establishes
a new potential model in studies of BC action, and has suggested
that BC supplementation may serve to replenish liver retinol stores
in infants/children while avoiding eventual unwanted effects of
early-life supplementation with pre-formed vitamin A on the sus-
ceptibility to obesity later in life [92].Impact of BC and BC derivatives on the metabolic proﬁle of
adipocytes
Impact on adipocyte fat storage capacity
Accumulating evidence links adipose BC and BC-conversion
products to the control of fat storage capacity of mature adipocytes
through suppression of PPARc. This nuclear receptor is required to
maintain the adipocyte phenotype [93] and to mediate high fat
diet-induced adipocyte hypertrophy [94] besides its essential role
in adipocyte differentiation. Characterized PPARc target genes
code for proteins that facilitate uptake, cytosolic binding and acti-
vation of fatty acids for triacylglycerol synthesis and lipid droplet
formation and maintenance ([95] and references therein).
Reduction of PPARc activity in mature adipocytes results in fat
mobilization [93].
In mice, changes of adiposity in response to vitamin A status
correlate with changes of PPARc expression in WAT depots: both
parameters are decreased after atRA treatment and increased afterFig. 3. Proposed action of local b-carotene (BC) adipose stores in obesity. BC and possibly
and (through the action of BCO1, not shown) as the precursors of retinoids such as retino
enhancing energy utilization. These activities may help counteracting adipose tissue pa
However, BC is consumed in the course of these activities. If the obesogenic conditions p
result in a reduced capacity to scavenge reactive species and for anti-adiposity retinoidchronic vitamin A deﬁcient diet feeding [58]. In mature 3T3-L1 adi-
pocytes, exposure to BC (2 lM) decreases lipid content and the
expression of PPARc and PPARc target genes while boosting the
production of atRA; these effects are dependent on BCO1 and
RAR, as they were abrogated by either a BCO1 inhibitor or a
pan-RAR antagonist [52]. Likewise, reduction of adiposity follow-
ing dietary BC supplementation in mice is linked to the suppres-
sion of PPARc and PPARc target genes in WAT, as indicated by
both transcriptomic and targeted gene and protein expression ana-
lysis, and BCO1-dependent (not seen in BCO1/ mice) [51].
Importantly, BC effects in 3T3-L1 adipocytes were not reproduced
upon incubation of the cells with vitamin A (retinol), suggesting
that BC is a key precursor for retinoid production in mature adipo-
cytes [52], and, in the animal study, evidence was provided of BC
accumulation in serum and WAT of BC-supplemented animals
[51]. Considered together, these results support the notion that a
BCO1-dependent, local production of retinoids from BC contributes
to the regulation of fat storage capacity in adipocytes (Fig. 3).
Remarkably, while BCO1-derived products repress PPARc, BCO1
itself is encoded in a PPARc target gene [96] that is induced during
adipocyte differentiation [52], which is suggestive of a negative
feed-back loop to keep control of PPARc. How retinoid-activated
RAR inhibits PPARc in mature adipocytes is not known, but
mechanisms similar to those involved in atRA inhibition of adipo-
genesis may be involved (see Section Impact of BC and BC deriva-
tives on adipogenesis).
White adipocytes are cells specialized in the storage of excess
dietary energy as triacylglycerol. Agents that repress adipogenesis
and/or reduce fat storage capacity of mature white adipocytes are
not necessarily beneﬁcial; on the contrary, they might be detri-
mental, especially under conditions of positive energy balance, as
they may boost ectopic fat deposition and lipotoxicity. This is not
the case for several carotenoids and carotenoid-derived products
with anti-adiposity action which, besides repressing PPARc, are
able to promote lipid oxidation in white adipocytes and other tis-
sues (see next).Impact on adipocyte capacity for oxidative metabolism/thermogenesis
Mammals possess different types of adipocytes, with important
differences among themregarding energymetabolism ([97] and ref-
erences therein). Brown adipocytes in typical brown adipose tissue
(BAT)depots are rich inmitochondria, have ahighoxidative capacity
and are specialized in the regulated production of heat (nonshiver-
ing adaptive thermogenesis) through oxidation of fatty acids andother provitamin A carotenoids in adipocytes may serve to scavenge reactive species
ic acid (RA) capable of repressing adipocyte hypertrophy by suppressing PPARc and
thological expansion under obesogenic conditions and keeping the individual lean.
ersist and the diet is defective in carotenoids, depletion of adipose BC stores would
signaling, thus contributing to the development of pathological obesity.
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trochemical gradient generated by the respiratory chain via uncou-
pling protein 1 (UCP1), an inner mitochondrial membrane protein
that behaves functionally as a proton transporter. Typical white adi-
pocytes in WAT depots are poor in mitochondria, have a low oxida-
tive capacity, do not express UCP1 and are specialized in the storage
and release of energy, according to biological needs. A third type are
the so-called ‘‘brite’’ (from brown-in-white) or ‘‘beige’’ adipocytes:
these are brown-like, UCP1-expressing adipose cells which can be
induced inWATdepots in response to cold anda variety of nutrition-
al and pharmacological factors, in a process known as browning
[97,98]. Brite adipocytes in WAT derive from precursor cells that
are different from those in classical BAT and are closer to the white
adipocyte cell lineage [97]. Brite cells may also arise from
white-to-brown transdifferentiation of white adipocytes [97].
Until recently, BAT was believed to play a negligible role in the
adult human and thought to be only present in neonates. However,
it has gained substantial interest since active BAT has been shown
to be present in adults and BAT activity is negatively associated
with increasing BMI in humans [99]. Increasing BAT activity and
inducing beige adipocytes in WAT both represent attractive strate-
gies to counteract obesity [100,101]. Moreover, in spite of the
widely neglected contribution of WAT to whole-body energy meta-
bolism, pharmacological and nutrient-dependent stimulation of
mitochondrial oxidative capacity and fatty acid oxidation in WAT
independent of UCP1 has been documented which may also con-
tribute to a lean phenotype [102]. Carotenoids and retinoids
impact on BAT thermogenic function, and on oxidative capacity,
mitochondrial genes and browning of WAT.
An interaction of carotenoids and retinoids with BAT function is
known for some time. Early work showed that BC and other provi-
tamin A carotenoids can induce UCP1 expression in cultured
brown adipocytes [103], possibly reﬂecting their local conversion
to atRA, which is a potent signal for UCP1 gene transcription in
brown adipocytes [56,104]. The retinoid responsiveness of the
UCP1 gene is explained by the presence in its promoter of both a
noncanonical retinoic acid response element and a PPAR response
element [105], and is mediated by RARs and RXRs [106] and also by
p38 mitogen-activated protein kinase (p38 MAPK) [107]. atRA
treatment in rodents leads to activation of BAT thermogenesis
including induction of UCP1 accompanying body weight and body
fat loss [56,57,108]. Moreover, feeding studies in rodents showed
the thermogenic capacity of BAT to be dependent on vitamin A sta-
tus, being decreased following a vitamin A-deﬁcient diet and
increased following a vitamin A (retinyl ester)-supplemented diet
[45,57,68], thus supporting a role of vitamin A as a physiological
regulator of the BAT thermogenic system.
More recently, retinoids have been shown to stimulate features
of WAT browning. Our pioneer work in this area demonstrated this
activity for atRA in mice [61] and in mature murine 3T3-L1 white
adipocytes in culture [109]. In the latter cells, atRA treatment led to
increased basal lipolysis and fatty acid oxidation rate, changes in
gene expression consistent with increased fatty acid mobilization,
oxidation and turnover and, upon prolonged treatment, decreased
intracellular lipid content [109]. Even if atRA treatment failed to
induce UCP1 in mature 3T3-L1 adipocytes [110,111], it potently
induced UCP1 in other murine models of white adipocytes, such
as adipocytes derived from primary mouse embryo ﬁbroblasts
(MEFs) and mature C3H10T1/2 adipocytes [110,111], in a p38
MAPK-dependent [110], RAR-dependent [111] and PPARc coacti-
vator 1a-independent manner [110,111]. In line with a browning
effect in vivo, atRA treatment in mice resulted in increased expres-
sion of mitochondrial, thermogenic and fatty acid oxidation genes
inWAT – including UCP1 protein in the subcutaneous (inguinal) fat
depot – and appearance in WAT of adipocytes with a multilocular
distribution of intracellular fat [61], the latter also a feature ofbrown adipocytes. atRA treatment has been shown to have compa-
rable effects in ferrets, in which acute treatment led to decreased
adiposity and increased multilocularity and UCP1 content in the
retroperitoneal adipose depot [54]. However, atRA failed to induce
UCP1 expression in human adipocyte cell lines and primary human
white adipocytes [111].
Not only atRA but also Rald has been implicated as an agent pro-
motingWAT browning. Rald was shown to induce UCP1 expression
inmature primaryMEFs-derived adipocytes, though at higher effec-
tive doses than atRA (10 lM vs 1 lM), as it can be expected for a Rald
effect following its intracellular conversion to atRA [110]. More
recently, Raldper sehasbeen implicatedas abrowningagent, largely
based onwork in Aldh1a1/mice. Deﬁciency of Aldh1a1 enhanced
cold-induced thermogenesis and induced a BAT-like transcriptional
program in visceral WAT of the knockout mice, without changes in
BAT [17]. Aldh1a1/ mice were previously shown to resist high
fat diet-induced obesity due to hypermetabolism [18]. Moreover,
WAT-selective Aldh1a1 knockdown in adult obese mice triggered
WAT browning while limiting weight gain and improving glucose
homeostasis [17]. The browning effect of Aldh1a1 deﬁciency has
been attributed to increased levels of its substrate, Rald, as evidence
was obtained of increased Rald levels in WAT of Aldh1a1/ mice
[18] and that Rald can induceUCP1expression in culturedwhite adi-
pocytes independently of its conversion to atRA, following binding
to and activation of RAR [17].
The similar phenotype of Aldh1a1/ mice, deﬁcient in the
major atRA generating enzyme, and atRA-treated mice is striking
and not completely understood [112]. Some considerations are
pertinent. First, it cannot be excluded that Rald-independent
effects contribute to the phenotype of Aldh1a1/ mice [17], since
Aldh1a1 can use other aldehyde substrates besides Rald [113].
Second, since atRA levels in WAT were not reported in the studies
by Ziouzenkova et al. 2007 [18] and Kiefer et al. 2012 [17], it is
unknown if decreased atRA levels accompanied the increased
Rald levels reported in WAT of Aldh1a1/ mice. Besides there
are enzymes redundant to Aldh1a1 for atRA generation in adipo-
cytes [38], atRA degrading enzymes such as CYP26A1 are expected
to be inhibited under conditions of Aldh1a1 deﬁciency (and thus
decreased atRA production) [114]. Notwithstanding other possible
explanations [112], it is quite possible that atRA and Rald have
somewhat redundant effects on adipose tissue metabolism.
Whereas browning effects of retinoids have been demonstrated
in white adipocytes in culture, rodents and ferrets (see above), evi-
dence for such an effect is lacking for BC. In mature 3T3-L1 adipo-
cytes, BC-derived atRA decreased lipid content and PPARc action,
but potential effects on browning-related genes were not investi-
gated [52]. In mice supplemented with BC, BC-derived retinoids
led to decreased adiposity and PPARc in WAT, but no evidence of
WAT browning was apparent from transcriptomic and morpho-
logical analysis of inguinal WAT [51]. Furthermore, in ferrets,
chronic intake of BC (3.2 mg/kg bw/day, 6 months) had opposite
effects than short-term atRA treatment and resulted in a decreased
presence of brown-like multilocular adipocytes and UCP1 in the
retroperitoneal depot [54]. This inhibitory effect cannot be
explained solely on the basis of inefﬁcient BC conversion into vita-
min A in the ferret [115], as this would have led to a neutral effect.
Differences in the potential of retinoids and BC as browning agents
and mechanisms involved deserve further investigation.Other carotenoids active in the modulation of adiposity
b-Cryptoxanthin
b-cryptoxanthin is a provitamin A carotenoid which displays
both structural and functional similarities to BC. Oral
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tained in 400 mg of a powder derived from Satsuma mandarins,
Citrus unshiu Marc., 8 weeks) lowered body weight, visceral adi-
pose tissue mass, adipocyte hypertrophy and serum lipid concen-
trations in a genetic obese mouse model (Tsumura Suzuki obese
diabetic), independent of changes in food intake [116].
Anti-obesity effects in rodents have also been reported for mango
(Mangifera indica L.) pulp (10% w/w) – which is a rich source of
b-cryptoxanthin, violaxanthin and BC [117].
The anti-adiposity effect of b-cryptoxanthin in rodents might be
in keeping with studies in differentiating 3T3-L1 adipocytes show-
ing reduction of lipid accumulation following exposure to
b-cryptoxanthin (1–10 lM) [24,118], although there are conﬂicting
results [119]. b-cryptoxanthin effects on adipogenesis entail RAR
activation and subsequent PPARc down-regulation [24]. Results
from in vitro nuclear receptor binding assays indicated that
b-cryptoxanthin can efﬁciently bind RARs (but not PPARc), which
raises the possibility that b-cryptoxanthin acts per se as a RAR ago-
nist to down-regulate PPARc in adipocytes [24].
Astaxanthin
Astaxanthin is a natural antioxidant, non-provitamin A carote-
noid, abundant in marine animals. Astaxanthin supplementation
(6–30 mg/kg bw/day) prevented visceral fat accumulation,
metabolic syndrome, and insulin resistance induced by high fat
diet feeding in mice and rats [120,121].The anti-adiposity action
of astaxanthin was not due to changes in food intake and was
traced to enhanced systemic fatty acid utilization, as indicated by
reduced respiratory quotient in indirect calorimetry tests [120].
Whether enhanced fat catabolism occurred in adipose tissue
depots was not addressed. Astaxanthin has also been shown to
inhibit rosiglitazone (a PPARc ligand)-induced adipogenesis of
3T3-L1 cells by antagonizing PPARc transcriptional activity, possi-
bly upon direct binding, since results of in vitro assays indicate that
astaxanthin is able to selectively bind PPARc (but not PPARa or
PPARb/d) [23].
Fucoxanthin
Fucoxanthin is an orange colored carotenoid present in edible
brown seaweeds, such as Undaria pinnatiﬁda (Wakame), Hijikia
fusiformis (Hijiki), Laminaria japonica (Ma-Kombu) and Sargassum
fulvellum. It is a non-provitamin A xanthophyll whose distinct
structure includes an unusual allenic bond (reviewed in [122]).
Fucoxanthin or fucoxanthin-rich seaweed extract, alone or as part
of mixtures with other selected agents, counteracts the develop-
ment of dietary obesity in obesity-prone mice fed a high fat diet
(when added to the diet at 0.05–2%, w/w) and reduces abdominal
WAT in genetically obese KK-Ay mice (when added to the diet at
0.2%) but not in normal mice fed a regular diet [122].
Fucoxanthin supplementation decreased WAT mass in obese ani-
mals by favoring fatty acid oxidation, UCP1 induction and heat pro-
duction in abdominal WAT [123]. Notably, fucoxanthin intake
promotes WAT browning at doses at which it does not affect
UCP1 expression in BAT, suggesting a WAT selective effect [123].
The actual mammalian targets for interaction with fucoxanthin
metabolites in fat cells remain to be identiﬁed, but enhancement
of the sensitivity of white adipocytes to sympathetic nerve
stimulation (which favors thermogenic activation) [124] and acti-
vation of AMP-dependent protein kinase (AMPK) [125] appear to
contribute to the fucoxanthin effects in WAT. In humans, weight
and adiposity reducing effects of fucoxanthin and Xanthigen™ 
a supplement commercialized for weight management which is a
source of fucoxanthin from brown seaweed plus pomegranate seed
oil extract rich in punicic acid, a conjugated linolenic acid  havebeen linked to increases of resting energy expenditure, which
may be related to the induction of browning by fucoxanthin
demonstrated in rodents [126].
Interaction of fucoxanthin with adipogenesis of preadipose cells
can also contribute to its anti-adiposity action, since suppressive
effects of fucoxanthin and its metabolite, fucoxanthinol (which is
found in WAT of fucoxanthin-treated animals) on adipogenesis of
3T3-L1 preadipocytes have been described when applied at inter-
mediate and late stages of the adipogenic process [127,128]. On
the opposite, fucoxanthin enhanced adipogenesis when applied
at an early stage (coincident with preadipocyte clonal expansion)
[128]. More recently, inhibition of 3T3-L1 preadipocyte differen-
tiation by Xanthigen™ has been reported and traced to
down-regulation of PPARc and C/EBPs, up-regulation of Sirtuin 1,
activation of AMPK and modulation of FoxO pathways [129].Other
Animal studies indicate an anti-adiposity action for some other
carotenoids. Dietary supplementation with crocetin
(50 mg/kg bw/day) – which is a natural antioxidant carotenoid
abundant in saffron, Crocus sativus Linn – prevented visceral fat
accumulation, metabolic syndrome, and insulin resistance induced
by high fat diet feeding in mice and rats, without affecting food
intake [49]. These effects were traced to enhanced hepatic fatty
acid oxidation [49]. Supplementation with violaxanthin-rich crude
thylakoids prepared from spinach leaves reduced body weight and
body fat gain in mice on a high fat diet without affecting energy
intake, suggestive of the involvement of a metabolic mechanism
[130].
Lycopene deserves an special mention since it is the second
most abundant carotenoid after BC in human fat tissue and it is
found at similar or even higher levels than BC in some other human
tissues [131]. Results indicate that lycopene does not exert an
anti-adiposity action. For instance, in obese Wistar rats lycopene
supplementation (10 mg/kg bw/day during 6 weeks) did not affect
body weight or adiposity [132], and cell studies showed no effect
of lycopene and apo-100-lycopenoic acid on adipogenesis [22].
However, apo-100-lycopenoic acid was shown to activate the RAR
and impact the transcription of certain RAR target genes in adipo-
cytes [22]. Moreover, lycopene has anti-inﬂammatory properties of
interest in obesity, including direct anti-inﬂammatory action in
adipocytes and obese WAT tissue (see next Section).Carotenoids and carotenoid derivatives as modulators of
adipose tissue secretory function, inﬂammation and oxidative
stress
Besides storing and releasing energy, WAT has an important
endocrine function: it actively participates in the systemic control
of energy balance, glucose homeostasis, insulin sensitivity, vascu-
lar haemostasis, inﬂammation and other processes through the
secretion of signaling molecules, among them many signaling pro-
teins (collectively named adipokines) produced by the adipocytes
and/or cells of the stromal-vascular fraction, often in concert. The
two roles of WAT are closely related to one another. Thus, the pro-
duction of many of these signals, including hormones and
immunomodulatory factors, is altered in obesity, which is nowa-
days recognized as a state of chronic, low-grade local (of WAT)
and systemic inﬂammation, which links central obesity to
metabolic disturbances as in the metabolic syndrome [33,133].
Both hypertrophic adipocytes and inﬁltrating macrophages in
WAT are a source of inﬂammatory mediators in obesity.
Carotenoids and carotenoid derivatives affect the secretory pro-
ﬁle of adipose tissue, including the production of speciﬁc
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scription factors and inﬂammatory pathways. Additionally, the
secretory proﬁle may be affected indirectly, i.e. secondarily to
effects on adipocyte lipid content and body fat.Impact on adipokines
Elevated levels of resistin, leptin and RBP4 have been associated
with inﬂammation and insulin resistance in humans and rodents
[134]. We and others have shown that exposure to atRA suppresses
the adipose production of leptin [57,108,135], resistin [59] and
RBP4 [62] in vivo and in adipocyte cell models, through transcrip-
tional mechanisms that involve both RAR- and RXR-dependent
pathways, as suggested by studies using receptor-speciﬁc agonists
[59,60,62]. Down-regulation of these adipokines paralleled an
enhancement of systemic insulin sensitivity in the atRA-treated
mice [59,62]. atRA-induced down-regulation has been demonstrat-
ed in humans besides rodents for leptin [135]. Remarkably, hepatic
expression of RBP4 was unaffected by atRA treatment that resulted
in down-regulation of RBP4 expression in WAT [62], pointing to an
adipocyte-speciﬁc effect; this is of interest, since it is the RBP4 of
adipose origin which has been related to inﬂammation and insulin
resistance (although any physical difference between hepatic and
adipose RBP4 remains to be established, to our knowledge).
Similar to atRA treatment, dietary vitamin A supplementation to
rodents resulted in decreased adipose expression and circulating
levels of resistin and leptin to an extent that largely exceeded
the reduction of adipose mass [59,60,68], whereas opposite
changes of leptin (i.e., up-regulation) were demonstrated in mice
fed a vitamin A deﬁcient-diet [57]. Moreover, transcriptome analy-
sis revealed leptin, RBP4 and resistin among the top ﬁfty
down-regulated genes in inguinal WAT of BC-supplemented
wild-type mice, and these effects were provitamin A-dependent,
as they were absent in BC-supplemented BCO1/ mice [51].
Adiponectin is an adipokine quite speciﬁc of adipocytes that is
down-regulated in obesity and with well-established
insulin-sensitizing, anti-inﬂammatory and anti-atherogenic action
[136]. Several carotenoids enhance adiponectin production in adi-
pocytes, through mechanisms still to be deﬁned. Paprika pigments,
which contain large amounts of the carotenoids capsanthin and
capsorubin, and crocetin from saffron have been shown to
up-regulate adiponectin in 3T3-L1 adipocytes and freshly isolated
rat adipocytes, respectively [137,138]. Fucoxanthin supplementa-
tion to mice on a high fat diet up-regulated adiponectin expression
in visceral WAT together with genes involved in fatty acid mobi-
lization and oxidation, and led to reduced body fat gain [139].
Lycopene supplementation to obese rodents increased adiponectin
in blood and mRNA expression of adiponectin in WAT independent
of changes in body weight or body fat content [140]. BC treatment
(20 lM, from days 4–8 of differentiation) induced adiponectin
expression in differentiating 3T3-L1 adipocytes [141], perhaps
through a provitamin A-independent effect, since in our hands
atRA treatment had no effect on adiponectin expression in
3T3-L1 adipocytes or adipose tissue of mice (Bonet, Ribot and
Palou, unpublished results) and even down-regulation of
adiponectin expression in WAT following acute atRA treatment
to rats (7.5 mg/kg, i.p. single dose) has been described [142].
Interestingly, an independent positive association between BC
and adiponectin levels in blood has been reported, both in general
population [143] and in non-diabetic obese adult human subjects
[144]. Other plasma/serum carotenoids tested in those human
studies, among them lycopene, did not show an association with
circulating adiponectin.Impact on adipose tissue inﬂammation
Anti-inﬂammatory properties of carotenoids have been demon-
strated in different contexts and tissues/cell types including adipo-
cytes and adipose tissue (reviewed in [13]). Anti-inﬂammatory
action is thought to arise from the ability of carotenoids to reduce
oxidative stress (see Section Impact on adipose tissue oxidative
stress) and to suppress NF-jB activation, thus inhibiting the down-
stream production of inﬂammatory cytokines [13].
At the adipocyte level, an anti-inﬂammatory action has been
best demonstrated for lycopene and fucoxanthin. Lycopene and
its metabolite, apo-100-lycopenoic acid, have been shown to inhibit
tumor necrosis factor alpha (TNFa)-mediated induction of
pro-inﬂammatory cytokine and chemokine
(macrophage-attractant signals) expression in both murine and
human adipocytes [22,145]. Similar results have been reported
for the fucoxanthin metabolite, fucoxanthinol [146]. Lycopene,
fucoxanthine and fucoxanthinol also attenuate the response of
RAW 264.7 macrophages to pro-inﬂammatory agents such as
lipopolysaccharide or palmitic acid [146–148]. This is of interest
because in the obese adipose tissue there is a vicious cycle between
adipocytes and macrophages contributing to inﬂammation, which
could be interrupted by these compounds. Inhibition of the NF-jB
pathway and of mitogen-activated protein kinase pathways (such
as the JNK pathway) underlies the anti-inﬂammatory action of
lycopene and fucoxanthin in adipocytes and macrophages
[145,148].
Anti-inﬂammatory action of fucoxanthin and lycopene has also
been demonstrated in vivo in adipose tissue of obese animals.
Genetically obese (KK-Ay) mice (but not lean mice) fed a
fucoxanthin-supplemented diet (0.2%) displayed a decreased
expression of pro-inﬂammatory factors and less inﬁltration of
macrophages in visceral WAT compared with control animals fed
the non-supplemented diet [146]. Likewise, treatment with fucox-
anthin led to decreased expression of pro-inﬂammatory factors,
myeloperoxidase activity (which attracts polymorphonuclear
blood cells) and macrophage inﬁltration in the mammary gland
of mice on a high fat diet [149]. In these two reports, fucoxanthin
supplementation/treatment also elicited an anti-adiposity action
[146,149]. As for lycopene, supplementation to obese Wistar rats
(10 mg/kg bw/day during 6 weeks) did not affect body weight or
adiposity, but decreased leptin, resistin, interleukin 6 and mono-
cyte chemoattractant protein-1 gene expression in gonadal adi-
pose tissue, and plasma concentrations of the former three
factors [132].Impact on adipose tissue oxidative stress
Oxidative stress generated in the obese adipose tissue is an
important pathogenic mechanism of obesity-associated metabolic
syndrome [32], tightly linked to adipose tissue inﬂammation and
secretion of systemic inﬂammatory mediators, since reactive spe-
cies activate inﬂammatory pathways, such as the NF-jB pathway.
Cell and in vivo studies have suggested that carotenoids have anti-
oxidant properties that stand from their ability to scavenge reac-
tive species such as singlet oxygen (1O2) and peroxyl radicals
and, especially, their ability to interact with and potentiate the
Nrf2 pathway, enhancing Nrf2 translocation to the nucleus and
the subsequent activation of the expression of a collection of anti-
oxidant and cytoprotective enzymes [13].
Although antioxidant properties of carotenoids have been pro-
ven in different tissues and cell types, reports dealing speciﬁcally
with antioxidant action in adipocytes or adipose tissue are scarce.
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reduce the production of reactive oxygen species (ROS) in cultured
adipocytes exposed to stressful agents such as palmitate or TNFa.
In the study of Kameji et al. (2010) [141], pre-treatment with BC
suppressed TNFa-induced ROS production, suggesting that intra-
cellular BC accumulation enables elimination of ROS in adipocytes.
In an intervention study in mice, astaxanthin treatment
(6 mg/kg bw/day) counteracted the development of diet-induced
obesity and insulin resistance and associated with decreased levels
of oxidative stress markers in adipose tissue and skeletal muscle of
the high fat diet-fed mice [121]. In another in vivo study, treatment
of mice on a high fat diet with fucoxanthin (0.4–0.6%) resulted in
lower body weight gain and suppressed maleic dialdehyde (used
as an indicator of oxidative stress) production and adipocyte
hypertrophy in the mammary gland, although analysis of classical
WAT depots was not included in this report [149].
It is known that carotenoids may act as antioxidants or proox-
idants depending on their concentration in cells, the cell oxidative
environment and other factors [150–153]. Carotenoid breakdown
products including highly reactive aldehydes (such as Rald) and
epoxides formed in the course of antioxidant action can increase
oxidative stress and impair mitochondrial function (including res-
piration), as shown in isolated rat liver mitochondria [154].
Additionally, studies in BCO2-deﬁcient mice indicate that carote-
noids in excess, if not properly detoxiﬁed by the activity of BCO2,
accumulate in mitochondria and cause oxidative stress leading to
mitochondria dysfunction [155] and the activation of the intrinsic
apoptotic pathway [156]. The latter studies were conducted mostly
in liver tissue and hepatic cells. Whether excess carotenoids or car-
otenoid breakdown products can contribute to oxidative stress
speciﬁcally in adipocytes/adipose tissue has not been reported, to
our knowledge. However, exposure of immortalized human prea-
dipocytes (Chub-S7) to BC (10–30 lM) resulted in decreased mito-
chondrial membrane potential, mitochondrial respiration and
cellular ATP content, indicative of an impaired mitochondrial func-
tion [157]. Most likely, as in other cell types and tissues, carote-
noids may protect adipocytes/adipose tissue against oxidative
stress or contribute to it, depending on the dose and cell/tissue
factors.Human studies linking carotenoids and vitamin A to body
adiposity
Human epidemiological studies
Studies in adults and children/adolescents have consistently
shown serum levels of carotenoids including BC to be decreased
in overweight and obese subjects (e.g. [158–161]). Moreover, sev-
eral large population-based, cross-sectional epidemiological stud-
ies have reported an inverse association between carotenoid
concentrations in blood and BMI and other measures of obesity
including adiposity, in some cases even when adjusted for other
factors associated with carotenoid concentration, such as intake
of fruit and vegetables, fat, ﬁber, alcohol, supplement use, smoking,
gender and lipid concentrations (e.g. [162–169]). Cross-sectional
studies have also reported lower serum carotenoid concentrations
in adults and children with the metabolic syndrome [170,171]. In
fact, independent associations of low serum carotenoids with risk
factors/biomarkers of the metabolic syndrome including increased
insulin resistance index (HOMA-IR), fasting insulinemia, oxidized
LDL, glycosylated hemoglobin, and circulating levels of inﬂamma-
tory markers such as C-reactive protein have been reported that
persisted after adjusting for confounders including BMI or relatedmeasures of obesity, and which are generally considered to be
related to antioxidant and anti-inﬂammatory activities of carote-
noids [167,172–179]. Cross-sectional and prospective studies fairly
consistently show that a higher intake and status of carotenoids is
associated with lower levels of low-grade inﬂammation in relation
to overweight, obesity and the metabolic syndrome [180].
The inverse association between carotenoid concentrations in
blood and BMI or adiposity may have different explanations. The
three more common are the following ([166] and references there-
in). First, BMI and serum carotenoids may be correlated because of
dietary and other lifestyle factors that affect them both. Second,
since serum carotenoids are partially fat soluble, adipose tissue
may act as a sink for them, so that relatively fewer are located in
the blood. However, the concentration of carotenoids in adipose
tissue and in isolated adipocytes is also lower in obese people
[27,29,181,182]. A recent report showed that isolated adipocytes
from obese subjects contain 50% lower concentrations of BC than
cells from lean or non-obese subjects [29]. Third, adipose tissue
in obesity may generate oxidative stress, and the carotenoids
may be lowered because of defending against this stress, and being
consumed upon their action as antioxidants. This latter explana-
tion could indeed explain decreased carotenoids levels in both
blood and adipose tissue in obesity.
Notwithstanding the aforementioned explanations, we believe
a mechanistic link cannot be ruled out in view of data indicating
that, in adipocytes, BC rather than retinol may function as the pre-
cursor for the local synthesis of retinoids capable of exerting an
anti-adiposity action [52]. Decreased BC per adipocyte in obesity
could reﬂect increased BC consumption in antioxidant reactions
needed to neutralize increased reactive species, and perhaps also
an attempt to counteract adipocyte hypertrophy under obesogenic
conditions by increasing retinoid production from BC. Whatever its
origin, if not corrected through dietary consumption, once estab-
lished decreased BC per adipose cell could contribute to the main-
tenance and further development of pathological obesity by
limiting BC-derived, anti-adiposity retinoid signaling (Fig. 3).
Moreover, human obese subjects may have a decreased efﬁciency
of BC conversion to retinoids compared to lean subjects which
could further contribute to the obese state: an inverse association
of BMI with BC conversion efﬁciency as assessed by a
stable-isotope reference method was demonstrated [183], and
another study found a slower rate of BC decline in serum after ces-
sation of dietary supplementation in individuals with the highest
BMI [184].
Whereas an inverse association of serum carotenoids with obe-
sity measurements is well established, an association of vitamin A
status as serum retinol levels with human obesity is less clear.
Some of the studies reporting an inverse association for carote-
noids found instead serum retinol to be constant across BMI values
or between obese and non-obese groups [158,160,163,168], likely
reﬂecting homeostatic regulation of circulating retinol through
controlled storage in and release from the liver. A recent study
reported higher concentrations of serum retinol (and lower of
serum carotenoids) to be associated with increased probability of
overweight and obesity in children [169]. Other studies, in over-
weight and obese (adult) subjects, found the opposite, i.e. lower
serum retinol to be associated with increased BMI [185,186].
Association of dietary intake of vitamin A or carotenoids as
evaluated through ad-hoc questionnaires with adiposity has also
been investigated. An inverse association between preformed vita-
min A intake after adjusting for total energy intake and several
measurements of adiposity  such as body weight, BMI, waist cir-
cumference and waist-to-hip ratio – has been reported in healthy
young adults [187]. Higher total carotenoid intakes, mainly those
Table 1
Beneﬁcial effects of carotenoid supplementation in the accrual of abdominal adiposity in humans.
Carotenoid source (dose) n Duration Change in waist
circumference
P Change in adiposity P Refs.
Encapsulated fruit and vegetable juice concentrate Juice
Plus (3.75 mg b-carotene/day)
30 children
(lean/obese)
6 months 1.47% vs +11.2%
in abdominal fatb,c
0.029 [190]
Jarrow Formulas CaroteneAll (3 mg mixed
carotenoids/day)
21 children
(obese)
6 months 4% in SATa,d
8% in VATa,c
0.016
0.041
[191]
Marine seaweed extract (12 mg fucoxanthin/day) 6 females 8 weeks 5.5 cma <0.001 [195]
Pomegranate seed oil plus brown seaweed extract
Xanthigen™ (2.4 mg fucoxanthin/day)
36 females
(obese)
16 weeks 5.6 cma <0.05 4.4 kg of total body
fata,c
<0.001 [126]
Satsuma mandarin-derived drink (0.5 mg b-
cryptoxanthin/day)
men (obese) 12 weeks 1.2 cma <0.05 13.5 cm2 of visceral
fat areaa,e
<0.01 [193]
a Relative to baseline values.
b Carotenoid supplemented group vs placebo group.
c Fat measured using a dual-energy X-ray absorptiometry scan (DEXA).
d Fat measured using a cross-sectional multi-slice MRI.
e Fat area measured using computed tomography (CT) cross-sectional images.
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circumferences and visceral and subcutaneous fat mass and lower
prevalence of metabolic syndrome in a cross-sectional study
involving middle-aged and elderly men (n = 374) [188]. A high
intake of carotenoids derived from a high consumption of vegeta-
bles and fruits, as in the Mediterranean diet, was shown to associ-
ate with lower development of metabolic syndrome traits
including increased waist circumference in a prospective study
involving 3232 subjects [189]. Altogether, the results of these stud-
ies point to an inverse association between dietary intake of vita-
min A and carotenoids and body adiposity.Human intervention studies
Despite the many animal studies and human epidemiological
studies linking carotenoids and carotenoid conversion products to
adiposity, there is a paucity of randomized controlled trials utilizing
dietary carotenoid supplementation to assess changes in adiposity,
and particularly visceral adiposity in relationship with components
of themetabolic syndrome. Such studieshavebeenconductedmain-
ly for BC, b-cryptoxanthin and fucoxanthin (Table 1).
Two small pilot double blind placebo-controlled studies in over-
weight and obese children using similar doses of BC (3–4 mg/day
as part of supplements) have recently reported signiﬁcant changes
in the 6 months rate of accrual in abdominal adiposity [190,191]. In
the ﬁrst of these two studies, lean and overweight children under-
went daily supplementation with an encapsulated supplement of
fruit and vegetable juice concentrate (providing approximately
3.75 mg of BC, 117 mg of vitamin C, 22.5 IU of vitamin E, 210 mg
of folate and 30 mg of calcium per day) or placebo in the presence
of nutritional counseling; the supplement led to increased serum
BC levels and resulted in a reduction in abdominal fat mass in con-
junction with an improvement in insulin resistance in the over-
weight children [190]. In the second study, obese children
completed a 2-weeks intense lifestyle intervention program fol-
lowed by 6 months of supplementation with Jarrow Formulas
CaroteneAll complex (providing daily 5000 IU of b- and
a-carotene, 20 mg of lutein, 4 mg of zeaxanthin, 20 mg of lycopene,
1 mg of astaxanthin and 20 mg of vitamin E) or placebo; in the
treatment group, reductions in both subcutaneous and visceral adi-
posity relative to baseline values were reported together with con-
comitant increases in serum adiponectin, while these parameters
changed in the opposite direction in the placebo group [191].
The administration of b-cryptoxanthin extracted from Satsuma
mandarin (0.5 mg/day as part of test drink) to moderately obese
Japanese males resulted in increased levels of b-cryptoxanthin in
serum and led to reductions in body weight, visceral fat and waistcircumference [192,193]. Another 3-weeks long study in seventeen
postmenopausal obese women supplemented with a beverage
containing b-cryptoxanthin (4.7 mg/day) reported no differences
in body weight or BMI but a 4-fold increase in adiponectin serum
levels after the treatment, suggestive of a reduction in adiposity (-
data on body fat mass were not include in this report) [194].
Regarding fucoxanthin, in a small randomized double blinded
placebo-controlled trial involving adult non-seaweed consuming
subjects in Ecuador with at least one symptom of metabolic syn-
drome, researchers showed that 6 g/day of dietary brown seaweed
containing fucoxanthin consumed for 2 months resulted in
decreased waist circumference in women and improved systolic
blood pressure [195]. Another 16 weeks study investigating the
effects of Xanthigen™ reported signiﬁcant reductions in body
weight, waist circumference, body fat content and serum triacyl-
glycerol in obese, non-diabetic female volunteers with
non-alcoholic fatty liver disease and normal liver fat content com-
pared to baseline, which were associated to increases in resting
energy expenditure [126].Concluding remarks
Carotenoids and carotenoids conversion products seem to play
a substantial role in the control of key aspects of adipose tissue
biology including the production of novel adipocytes from precur-
sor cells (adipogenesis), the metabolic and secretory capacities of
mature adipocytes and local inﬂammation through well-deﬁned
or emerging mechanisms. Because adiposity, particularly visceral
adiposity, is an important determinant of disease susceptibility
and adipose tissue represents a main reservoir for carotenoids
and retinol, it is conceivable that a putative beneﬁcial effect of car-
otenoids and retinoids on health is tightly linked to their local
effects in adipose tissue, counteracting features of the so-called
‘‘adiposopathy’’ or ‘‘sick fat’’ phenomena [196]. Animal studies sup-
port an anti-adiposity and anti-inﬂammatory action of carotenoids
and carotenoid derivatives in obesity. Interestingly, some of these
compounds – such as fucoxanthin, astaxanthin and the
BC-derived retinoids atRA and Rald – exert both suppressive effects
on PPARc activity and adipogenesis and activating effects on lipid
oxidation and thermogenesis in mature adipocytes and other cell
types. Such compounds might, therefore, help in moderating the
formation of new adipocytes under obesogenic conditions while
simultaneously favoring the dissipation of excess energy. Human
epidemiological studies reveal a low intake and nutritional status
of carotenoids among obese subjects, including obese chil-
dren/adolescents, which needs to be critically addressed. So far,
there have been limited human intervention studies with
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posity or obesity-related co-morbidities; even if these studies are
insufﬁcient to prove a cause-effect relationship, the scenario they
depict is encouraging, since both in children and adults the inter-
ventions had beneﬁcial effects on the accrual of body fat, abdom-
inal fat and related risk parameters (Table 1).
Despite epidemiological evidence linking carotenoid intake in
the form of fruits and vegetables to decreased risk of certain dis-
eases, a number of intervention trials have shown limited if any
preventive beneﬁt of relatively large doses of carotenoids and par-
ticularly BC on disease incidence, and even in some cases
long-term supplementation has proven to be harmful in people
at risk for disease, such as smokers [197]. This might relate to
the fact that dual pro- and anti-oxidant effects as well as gene
expression modulation by carotenoids and their derivatives may
be concentration-dependent phenomena, affected as well by addi-
tional factors, including components of the food matrix, cellular
conditions, and features of the individual affecting carotenoid
bioavailability and requirements, among them genetic variability
[198] and, as suggested here, body composition. Optimal upper
and lower carotenoid levels to achieve beneﬁt based on body com-
position and other interacting factors are yet to be clearly deﬁned.
Importantly, beneﬁcial effects of BC supplements on adiposity in
humans have been achieved under mild BC supplementation, at
doses quite lower than the ones that caused concern and contro-
versy in large intervention trials, and in obese people.
There are more than 600 carotenoids in nature and many of
them possibly capable of interacting with cellular machineries
and signaling pathways to elicit potential beneﬁcial effects. These
compounds entail, therefore, a vast potential to tackle health prob-
lems, as illustrated here for obesity and some of its co-morbidities.
However, more human intervention studies are needed to verify
this potential for speciﬁc carotenoids, and more functional and
mechanistic studies are needed to fully understand the connection
of carotenoids with the control of adiposity. At the same time, the
identiﬁcation and characterization of novel sources of carotenoids
can help regional economic development through the exploitation
of autochthonous edible or cultivatable carotenoid sources.
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